Among patients with schizophrenia, long-term antipsychotic use does not appear to increase severe physical morbidity or somatic hospitalization, and mortality is lower for antipsychotic use compared with no use.
The findings suggest that factors such as antipsychotic treatment, diet, or lifestyle may contribute to weight gain in patients with long-term disease.
Current antipsychotic therapy, effective primarily for positive symptoms but limited with negative symptoms, may be related to serious adverse effects, including motor impairments, prolactin abnormalities, and cardiometabolic disturbances.
The researchers noted that recent stressful life events, perceived stress, daily cortisol levels, and high sensitivity C-reactive protein levels accounted for 78% of the variance between women with postpartum psychosis and healthy controls and 46% of the variance between at-risk women and healthy controls.
Symptom reduction was significantly correlated with poor metabolic adverse effects, including weight gain, elevated BMI, and higher total cholesterol.
The investigators recommended revising the CAPE-P15 cutoff thresholds to 1.30 and 1.29 for the frequency and distress subscales, respectively. These cutoff values have high sensitivity for psychotic experiences.
Researchers conducted a case-control study to examine the associations between polygenic risk scores for schizophrenia and other mental disorders with the development of cannabis use disorder.
The Food and Drug Administration (FDA) has approved Caplyta (lumateperone; Intra-Cellular Therapies), an atypical antipsychotic, for the treatment of schizophrenia in adult patients.
Investigators assessed the influence of polygenic risk score on white matter microstructure, which is known to be impaired in individuals with schizophrenia, bipolar disorder, and their relatives.
Theories of schizophrenia pathophysiology have linked dopamine function with positive symptoms, as well as disrupted salience processing.